Dyne Therapeutics Net Income From Continuing Ops Over Time
| DYN Stock | USD 15.38 0.10 0.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dyne Therapeutics Performance and Dyne Therapeutics Correlation. Will Biotechnology sector continue expanding? Could Dyne diversify its offerings? Factors like these will boost the valuation of Dyne Therapeutics. Projected growth potential of Dyne fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dyne Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Dyne Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dyne Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Dyne Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income From Continuing Ops Analysis
Compare Dyne Therapeutics and related stocks such as Ultragenyx, Soleno Therapeutics, and Centessa Pharmaceuticals Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RARE | (59.8 M) | (59.8 M) | (59.8 M) | (59.8 M) | (59.8 M) | (145.6 M) | (245.9 M) | (302.1 M) | (197.6 M) | (402.7 M) | (186.6 M) | (454 M) | (707.4 M) | (606.6 M) | (569.2 M) | (512.3 M) | (537.9 M) |
| SLNO | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (13.9 M) | (15.7 M) | (12.1 M) | (12.1 M) | (11.8 M) | (30.8 M) | (24.6 M) | (30.9 M) | (24.1 M) | (33.2 M) | (175.8 M) | (158.3 M) | (150.4 M) |
| CNTA | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (5.1 M) | (10.7 M) | (216.2 M) | (216.2 M) | (157.4 M) | (235.8 M) | (212.2 M) | (201.6 M) |
| XENE | 12 M | 12 M | 12 M | 12 M | 13 M | (15.8 M) | (23 M) | (30.7 M) | (38.9 M) | (41.6 M) | (28.8 M) | (78.9 M) | (125.4 M) | (175 M) | (234.3 M) | (210.9 M) | (200.4 M) |
| APGE | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (39.8 M) | (84 M) | (182.1 M) | (163.9 M) | (155.7 M) |
| AAPG | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (677.6 M) | (782.4 M) | (882.9 M) | (925.7 M) | (405.7 M) | (466.5 M) | (489.9 M) |
| MIRM | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (26 M) | (52.6 M) | (103.3 M) | (84 M) | (135.7 M) | (164.2 M) | (87.9 M) | (79.1 M) | (83.1 M) |
| CELC | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (2.3 M) | (3.3 M) | (6.3 M) | (7.5 M) | (7.4 M) | (9.5 M) | (29.6 M) | (40.4 M) | (56.5 M) | (111.8 M) | (100.6 M) | (95.6 M) |
| TLX | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (44.9 M) | (80.5 M) | (104.1 M) | 5.2 M | 49.9 M | 57.4 M | 60.3 M |
| CGON | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (12.8 M) | (35.4 M) | (48.6 M) | (88 M) | (79.2 M) | (75.3 M) |
Dyne Therapeutics and related stocks such as Ultragenyx, Soleno Therapeutics, and Centessa Pharmaceuticals Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Dyne Therapeutics | DYN |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 1560 Trapelo Road, |
| Exchange | NASDAQ Exchange |
USD 15.38
Check out Dyne Therapeutics Performance and Dyne Therapeutics Correlation. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Dyne Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.